Friday, 16 October 2026European Markets

HOTELS DE PARIS Stock Impressive Jump On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with hotels de paris (hdp.pa) rising 12.32% to €3.10 on tuesday, after three consecutive sessions in a row of losses. cac 40 rose 1.39% to €7,185.68, following the last session's upward trend on what was an all-around bullish trend exchanging session today.

hotels de paris's last close was €2.76, 18.34% under its 52-week high of €3.38.

about hotels de paris

les hôtels de paris sa operates and manages hotels in paris. it also offers restaurant and bar services. the company operates hotels in paris, st tropez, and marrakech. les hôtels de paris sa was incorporated in 1992 and is headquartered in paris, france.

earnings per share

as for profitability, hotels de paris has a trailing twelve months eps of €-0.4.

more news about hotels de paris (hdp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com